Abstract:Purpose There is increasing evidence for convincing efficacy and safety of 177Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of 177Lu-labled PSMA-targeted RLT in East Asians. The present study summarized the first experience with 177Lu-PSMA-I&T therapy for mCRPC in China. Methods Forty consecutive patients with mCRPC were enrolled from December 2019 to September 2021. Eligible patients received 177Lu-PSMA-I&T RLT at intervals of 8-12 weeks. Toxicity was assessed based on standardized physicians’ reports and the Common Toxicity Criteria for Adverse Events criteria. Response to PRLT was evaluated according to the changes of prostate specific antigen (PSA) response and imaging response. Quality of life (QOL), Karnofsky performance status (KPS) and pain (visual analogue scale, VAS) were also evaluated. The impacts of baseline parameters on the therapeutic effects were explored by univariate and multivariate logistic regression analyses. Results All patients underwent a total of 86 cycles of 177Lu-PSMA-I&T (range: 1-5 cycles) with dosages of 3.70-14.43GBq per cycle, with a median of 8 months followed up. Six patients (15%) developed mild reversible xerostomia during follow-up, and 28 patients (70%) experienced grade 1-4 bone marrow dysfunction. Changes in PSA were assessed after therapy, accompanied by the partial response (PR) in 25 patients (62.5%), the stable disease (SD) in 5 patients (12.5%), and the progressive disease (PD) in 10 patients (25%), respectively. QOL, KPS (%) and VAS scores were improved significantly due to treatment (P<0.05). Overweight and elevated AST, ALP, and LDH were associated with poor outcomes. Conclusions 177Lu-PSMA-I&T achieves the favourable response and well tolerance in mCRPC, which associates with not only PSA decline but also with tumor remission including lymphadenopathy and bone metastasis. We also find that patients with overweight and high AST, ALP, and LDH should be cautious to undergo the PRLT. Large-cohort studies are warranted to confirm the initial findings and elucidate the survival benefit of the treatment.

177Lu-Dotatate Therapy in a Case of Castrate-Resistant Prostate Cancer with Neuroendocrine Differentiation

177 Lu-DOTATATE Therapy in a Case of Castrate-Resistant Prostate Cancer With Neuroendocrine Differentiation

Case report: 177Lu DOTA-TATE: a new scheme for the treatment of prostate neuroendocrine cancer

177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer

Dual 177Lu–Prostate-Specific Membrane Antigen and 177Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation

¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

Metastatic Prostate Adenocarcinoma with Neuroendocrine Differentiation on 18F-FDG PET/CT, 68Ga-Psma PET/CT and 68Ga-Dota TATE PET/CT with Injected Ultra-Low-activity

Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient with Treatment-Related Neuroendocrine Prostate Cancer with Urinary Retention and Rectal Obstruction: A Case Report

Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177Lu-PSMA

Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225Ac-PSMA-617

Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F–Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL

Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer

Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China

A Phase 1 Trial to Determine the Maximum Tolerated Dose and Patient-Specific Dosimetry of [177Lu]lu-Lnc1003 in Patients with Metastatic Castration-Resistant Prostate Cancer.

Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3

The role of Ga68 PSMA PET/CT imaging in Lu177 PSMA treatment planning in metastatic castration-resistant prostate cancer

177Lu-Psma-i&t Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

PSMA‑Targeted Radioligand Therapy with the Radiopharmaceutical 177Lu‑PSMA‑617 in a Patient with Metastatic Castration‑Resistant Prostate Cancer

Efficacy and Safety of 225Ac-DOTATATE in the Treatment of Neuroendocrine Neoplasms With High SSTR Expression

A Rare Case of Neuroendocrine Prostate Cancer Detected on 68Ga - DOTANOC Positron Emission Tomography/Computed Tomography (PET/CT)

177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases